Alopexx, Inc. (ALPX) Plans to Raise $15 Million in October 12th IPO
Alopexx, Inc. (ALPX) Plans to Raise $15 Million in October 12th IPO
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".$Alopexx (ALPX.US)$ plans to raise $15 million in an initial public offering on Wednesday, October 12th, IPO Scoop reports. The company plans to issue 3,000,000 shares at $5.00 per share.
$Alopexx (ALPX.US)$計劃在 10 月 12 日（週三）首次公開募股中籌集 1500 萬美元，IPO Scoop 報導。該公司計劃以每股 5.00 美元的價格發行 300 萬股股票。
Alopexx, Inc. has a market-cap of $39.2 million.
阿洛比克斯公司的市值為 3,920 萬美元。
ThinkEquity acted as the underwriter for the IPO.
思想是首次公開招股的承銷商。
Alopexx, Inc. provided the following description of their company for its IPO: "We are a clinical stage biotechnology company developing novel immune therapeutics for the prevention, treatment and mitigation of bacterial, fungal and parasitic infections that express the antigenic target poly N-acetyl glucosamine (PNAG). That target has been found on an expanding number of pathogens. While the ultimate decision on the safety and efficacy of our therapeutics will be determined by the FDA and other health authorities, it is our management's assessment that the broad-spectrum potential of our therapeutics will allow them to be used for the prevention, treatment, and mitigation of a wide range of infections. In a first-in-man trial, our vaccine candidate, AV0328, has been shown to be well tolerated with no serious adverse events observed. It was noted to induce protective antibodies against all PNAG-expressing pathogens tested. We believe our vaccine's broad-spectrum potential will allow it to be used for the long-term prevention of a wide range of infections, including pneumococcal pneumonia, methicillin-resistant Staphylococcus aureus (MRSA), meningitis and sexually transmitted diseases. Similarly, our fully human monoclonal antibody, F598, which also targets PNAG, has been shown to be well tolerated and no serious adverse events were noted in phase 1 and pilot phase 2 trials. We believe it can provide immediate protection lasting 2-3 months. We seek to establish F598 as the standard of care for preventing and ameliorating gram-negative and gram-positive bacterial infections along with fungal infections by organisms that express PNAG in patients admitted to intensive care units (ICU). Utilization of these therapeutics also has potential applicability beyond infectious diseases, including treatment of neurological conditions and cognitive decline due to inflammation. Note: Net loss is for the year ended Dec. 31, 2021. **Note: As of June 30, 2022, we had an accumulated deficit of $5.99 million. Alopexx says that it has three officers and no employees before the IPO, according to the prospectus. (Note: Alopexx increased the size of its IPO to 3.0 million shares, up from 2.5 million shares, and cut the price to $5.00, the bottom of its previous $5.00-to-$7.00 range, to raise $15 million (same estimate as before), according to an S-1/A filing dated Sept. 6, 2022. Alopexx disclosed its IPO terms – 2.5 million shares at $5.00 to $7.00 to raise $15 million – in an S-1/A filing dated Aug. 24, 2022. Alopexx filed an S-1/A dated April 20, 2022, disclosing that its proposed stock symbol is "ALPX". On March 4, 2022, Alopexx filed its S-1. The company filed confidential IPO documents with the SEC on Jan. 7, 2022.) ".
Aleopexx, Inc. 為其公司的 IPO 提供了以下描述：「我們是一家臨床階段的生物技術公司，開發新穎的免疫療法，用於預防，治療和緩解細菌，真菌和寄生蟲感染，這些感染表達抗原靶標聚 N-乙酰葡萄糖胺（PNAG）。該目標已在不斷擴大的病原體上發現。儘管我們治療的安全性和有效性的最終決定將由 FDA 和其他衛生當局決定，但我們管理層的評估是，我們治療藥物的廣譜潛力將使它們能夠用於預防，治療和緩解各種感染。在首次人體試驗中，我們的候選疫苗 AV0328 已被證明具有良好的耐受性，沒有觀察到嚴重的不良事件。有人指出，誘發對測試的所有 PNA 表達的病原體的保護性抗體。我們相信，我們的疫苗具有廣譜潛力，可用於長期預防各種感染，包括肺炎球菌肺炎、耐甲氧西林金黃色葡萄球菌（MRSA）、腦膜炎和性傳播疾病。同樣地，我們的全人類單克隆抗體 F598 也針對 PNAG，已被證明具有良好的耐受性，並且在第一階段和試驗 2 期試驗中沒有發現嚴重的不良事件。我們相信它可以提供持續 2-3 個月的即時保護。我們力求建立 F598 作為預防和改善革蘭氏陰性和革蘭氏陽性細菌感染的護理標準，以及在入住重症監護病房（ICU）的患者中表達 PNAG 的生物的真菌感染。這些療法的利用還具有傳染性疾病以外的潛在適用性，包括治療神經系統疾病和由於炎症引起的認知能力下降。註：淨虧損為截至 2021 年 12 月 31 日止年度的淨虧損。** 註：截至 2022 年 6 月 30 日，我們的累計赤字達 599 萬美元。根據招股說明書，Aleopexx 表示，在首次公開募股之前，它有三名官員和沒有員工。（注意：Aloopexx 將其首次公開募股規模增加到 300 萬股，從 250 萬股增加，並將價格下調至 5.00 美元，這是之前 500 美元至 7.00 美元範圍的底部，以籌集 1,500 萬美元（與之前相同的估計值），日期為 2022 年 9 月 6 日的 S-1/A 備案。在日期為 2022 年 8 月 24 日的 S-1/A 檔案中，阿洛比克斯披露了其首次公開招股條款 — 250 萬股，價格為 5.00 美元至 7.00 美元，以籌集 1,500 萬美元。阿洛比克斯於 2022 年 4 月 20 日提交了 S-1/A，披露其建議的股票代碼為「ALPX」。2022 年 3 月 4 日，阿洛比克提交了 S-1。該公司於 2022 年 1 月 7 日向美國證券交易委員會提交了機密 IPO 文件。
Alopexx, Inc. was founded in 2006 and has 0 employees. The company is located at 186 Alewife Brook Pkwy #1068 Cambridge, Massachusetts 02138 and can be reached via phone at (617) 780-1598 .
阿洛比克斯股份有限公司成立於 2006 年，現有 0 名員工。該公司位於 186 阿萊斯布魯克公司 #1068 劍橋, 馬薩諸塞州 02138 並且可以通過電話到達 (617) 780-1598.
譯文內容由第三人軟體翻譯。
